A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far...

Area of Science:

• Immunology
• Vaccinology
• Clinical Trials Methodology

Background:

• Traditional vaccine clinical trials involve blood sampling from all participants.
• The test-negative immune correlates design offers a potentially more efficient alternative by sampling only symptomatic participants.

Purpose of the Study:

• To compare the efficacy of traditional versus test-negative immune correlates methods.
• To evaluate these methods within the context of the mRNA-1273 SARS-CoV-2 vaccine efficacy clinical trial.

Main Methods:

• Comparative analysis of two immune correlates designs: traditional and test-negative.
• Utilized neutralizing and binding antibody assays.
• Hazard ratios were calculated for both methods in the SARS-CoV-2 vaccine trial.

Main Results:

• Hazard ratios for neutralizing antibodies were 0.48 (traditional) and 0.55 (test-negative).
• Hazard ratios for binding antibodies were 0.69 (traditional) and 0.78 (test-negative).
• Results indicate comparable performance between the two methods.

Conclusions:

• The test-negative immune correlates design is a logistically simpler approach.
• This design provides reliable immune correlate data for vaccine efficacy trials.
• Supports the adoption of the test-negative design for future vaccine research.